Future Directions in the Treatment of Osteosarcoma

Future Directions in the Treatment of Osteosarcoma

Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of outcome. Outcomes for patients with osteosarcom...

Full description

Bibliographic Details
Main Authors: Alannah Smrke, Peter M. Anderson, Ashish Gulia, Spyridon Gennatas, Paul H. Huang, Robin L. Jones
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cells
Subjects:
osteosarcoma
chemotherapy
MAP
immunotherapy
genomic heterogeneity
adolescent and young adult
Online Access:https://www.mdpi.com/2073-4409/10/1/172

Internet

https://www.mdpi.com/2073-4409/10/1/172

Similar Items